If the neurointerventional space is going to reduce its existing microplastics burden, “small, intuitive changes” made by physicians and companies alike may be an important initial step in the right direction. This is among the major messages Sophia Hohenstatt (Heidelberg, Germany) delivered while speaking to NeuroNews at the 2025 BRAIN conference (1–3 December, London, UK).
In this video interview, Hohenstatt outlines the motives and key findings of her ongoing research into the presence of microplastics within neurovascular care, including a trend towards increased microplastics levels in stroke patients’ blood samples as compared to control groups. She also discusses the ramifications of these data, potential areas that future studies may focus on, and the role medical device companies can play in mitigating the burden of microplastics moving forward.
